Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal
35 Pages Posted: 20 Jul 2020 Publication Status: PublishedMore...
The beginning of the twenty-first century has been marked by three distinct waves of zoonotic coronavirus outbreaks into the human population. The current pandemic COVID-19 (Coronavirus disease 2019) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a rapid infection rate, it is a global threat endangering the livelihoods of millions worldwide. Currently, and despite the collaborative efforts of governments, researchers, and the pharmaceutical industries, there are no substantially significant treatment protocols for the disease. To address the need for such an immediate call of action, we leveraged the largest dataset of drug- induced transcriptomic perturbations, public SARS-CoV-2 transcriptomic datasets, and expression profiles from normal lung transcriptomes. Our unbiased systems biology approach not only shed light on previously unexplored molecular details of SARS-CoV-2 infection (e.g., interferon signaling, inflammation and ACE2 co-expression hallmarks in normal and infected lungs) but most importantly prioritized more than 50 repurposable drug candidates (e.g., Corticosteroids, Janus kinase and Bruton kinase inhibitors). Further clinical investigation of these FDA approved candidates as monotherapy or in combination with an antiviral regimen (e.g., Remdesivir) could lead to promising outcomes in COVID-19 patients.
Funding: This work is partially supported by a Discovery Grant from the National Sciences and Engineering Research Council of Canada (RGPIN/06101-2014) and an operating grant from the Cancer Research Society (OG24054). M.R holds a Fonds de la Recherche en Santé du Québec Junior II Award.
Conflict of Interest: All authors declare no conflict of interest.
Suggested Citation: Suggested Citation